From product knowledge to responsible engagement: What pharma’s frontline workforce needs today? 

Anindita Banik, Co-Founder & CEO, SmartWinnr, discusses why pharmaceutical companies need to move beyond product knowledge and equip medical representatives to handle doctor interactions with accuracy, confidence and compliance 

In a crowded OPD, a medical representative (MR) gets a few minutes with the doctor. The MR knows the brand’s data cold. The doctor asks, “Is this safe for my elderly patients?” 

The quickest reply perhaps is “Completely safe, doctor.” That answer can land the pharmaceutical company in trouble. Under the Uniform Code for Pharmaceutical Marketing Practices (UCPMP 2024), the word “safe” must not be used without qualification. The code holds companies responsible for their MRs’ conduct. The CEO answers for adherence, and the company’s executive head files an annual disclosure and compliance declaration. 

The scrutiny is growing. In September, the Supreme Court reserved its order on a plea to regulate pharma marketing. The Centre proposed a three-member committee to examine whether a law is needed, and the code applies until then. Since May 2025, as per the DGHS order, MRs are not permitted in central government hospitals. It says they may share updates “by email or other digital media”. 

Product knowledge gets an MR initial access, but what the MR says next determines whether the doctor trusts the brand or not. Those few minutes have to be accurate, compliant, and useful to the doctor. 

Too much field training is still judged by completion rates and quiz scores. Both show what an MR remembers, not how they handle a doctor who pushes back.

That gap shows up in a handful of moments: a safety question, a query about an unapproved use, a comparison with a competitor, or a request that crosses a line, such as a doctor asking the company to sponsor a conference trip. The code bars that unless the doctor is speaking at a CME or CPD program.

On safety, the evidence is sobering. When doctors in Canada, France and the US reported on 1,692 sales-rep promotions, serious side effects came up in only 5 to 6% of them, according to a 2013 study in the Journal of General Internal Medicine. Managers can’t hear most calls, so moments like these rarely get coached.

Imagine the same MR in a team that gets trained for these scenarios. The safety question would not be a surprise. 

Weeks earlier, at the cycle meeting, the brand, medical affairs and compliance teams list the questions MRs are most likely to fumble and agree on what good answers sound like. “Is it safe for my elderly patients?” is on the list. So is the doctor who asks about an unapproved use, and the one who wants a conference trip sponsored. The list keeps changing. When the prescribing information is updated, or a new question starts coming up in the field, the scenarios change with it. 

The MR rehearses each scenario with an AI-simulated doctor on the phone and gets scored every time. The feedback is specific: “You called it safe without qualifying it.” “You skipped the side effects in the prescribing information.” “You didn’t offer the leaflet. 

The bar is agreed in advance with medical and compliance. The answer has to be accurate, every safety statement has to be qualified, and the MR has to recognize when a question belongs with the medical team. Every MR is held to the same bar. A new joiner may simply need more attempts to reach it than a veteran. 

The area manager watches a couple of those attempts before joint field work, coaches the one habit that matters, and signs off only when the MR clears the bar. In the field, the manager checks the same things. 

The manager stays in the loop for a reason. A randomized field experiment with sales agents outside pharma, published in the Journal of Marketing, found that AI coaching combined with a manager’s coaching beat either one alone. 

This does not make the doctor’s question easier. It means the MR has practiced it and is better prepared for the actual conversation with the doctor. 

When the DGHS order came out last year, the Indian Pharmaceutical Alliance asked for “a balanced, structured and transparent engagement model”. The government may yet write one into law. Companies don’t need to wait. The model can start inside the field force: a short list of scenarios that matter, practice before the first call, and managers who coach from what they’ve seen. For a sales head, the test is simple. Before an MR walks into a doctor’s chamber, can you show they can handle the questions most likely to go wrong? If the only evidence is a quiz score, it’s time to measure something else. 

Indian Pharmaceutical AllianceSmartWinnr
Comments (0)
Add Comment